The BCR signalling pathway is therapeutically promising, and recent data indicate that it might be important in the pathogenesis of B-CLL and DLBCL. Its importance in MCL was suggested by gene expression studies. We show that tonic BCR signalling might be one of the mechanisms driving cell survival and proliferation in MCL, and that the inhibition of SYK might be a viable therapeutic approach. More studies are needed to verify the importance in vivo of this pathway